Abstract: Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.

Abstract: Systems and methods are described herein that provide a system associated with a CRA application framework with offline capability for mobile devices. In one example embodiment, a network request is received via network communications from a mobile device. The request is identified and multiple processing threads are initiated that separate operations for performing the request. A Self Describing Object (SDO) is generated and is returned in response to a fetch request. This allows the mobile device to input data while offline from a server and to minimize network interactions therebetween.

Abstract: The invention includes methods and compositions for treating a metabolic disorder, such as metabolic syndrome, hyperlipidemia and associated disorders, such as obesity and diabetes. The invention includes a method of treating a human subject comprising administering 12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME) to the subject. Further provided is the use of 12,13-diHOME as a biomarker for identifying brown adipose tissue (BAT) activation in human subjects.

Abstract: The invention provides methods and compositions relating to molecular targets identified as being capable of increasing or decreasing thermogenic potential in cells, including preadipocytes. Included in the invention are methods and compositions relating to inhibiting or suppressing the activity of an uncoupling protein 1 (UCP1) negative regulator, such as cardiac actin 1 (ACTC1), somatostatin receptor 1 (SSTR1), FAT atypical cadherin 1 (FAT1), and protein tyrosine phosphatase receptor type B (PTPRB). Also included in the invention are methods and compositions relating to activating a UCP1 positive regulator, such as phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 1 (PREX1), cortactin binding protein 2 (CTTNBP2), doublesex and mab-3-related transcription factor-like family A1 (DMRTA1), and endothelin receptor type B (ENDRB). The invention also provides methods and compositions relating to enrichment of cells having thermogenic potential based on cell surface markers, e.g.

Abstract: Systems and methods are described herein that provide a system associated with a CRA application framework with offline capability for mobile devices. In one example embodiment, a network request is received via network communications from a mobile device. The request is identified and multiple processing threads are initiated that separate operations for performing the request. A Self Describing Object (SDO) is generated and is returned in response to a fetch request. This allows the mobile device to input data while offline from a server and to minimize network interactions therebetween.

Abstract: The invention includes methods and compositions for treating a metabolic disorder, such as metabolic syndrome, hyperlipidemia and associated disorders, such as obesity and diabetes. The invention includes a method of treating a human subject comprising administering 12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME) to the subject. Further provided is the use of 12,13-diHOME as a biomarker for identifying brown adipose tissue (BAT) activation in human subjects.

Abstract: The invention provides methods and compositions relating to molecular targets identified as being capable of increasing or decreasing thermogenic potential in cells, including preadipocytes. Included in the invention are methods and compositions relating to inhibiting or suppressing the activity of an uncoupling protein 1 (UCP1) negative regulator, such as cardiac actin 1 (ACTC1), somatostatin receptor 1 (SSTR1), FAT atypical cadherin 1 (FAT1), and protein tyrosine phosphatase receptor type B (PT-PRB). Also included in the invention are methods and compositions relating to activating a UCP1 positive regulator, such as phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 1 (PREX1), cortactin binding protein 2 (CTTNBP2), doublesex and mab-3-related transcription factor-like family A1 (DMRTA1), and endothelin receptor type B (ENDRB). The invention also provides methods and compositions relating to enrichment of cells having thermogenic potential based on cell surface markers, e.g.

Abstract: Systems and methods are described herein that provide a mobile push notification system that sends notifications to various types of mobile devices using a single cloud based interface. One example embodiment includes a registration logic configured to receive device data from a mobile device. A record of the device data is stored in a database. A token generator creates a registration token that identifies the mobile device. The registration logic is facilitates communication between the mobile device and a vendor service when the registration token is received from the mobile device.

Abstract: Systems and methods are described herein that provide a mobile push notification system that sends notifications to various types of mobile devices using a single cloud based interface. One example embodiment includes a registration logic configured to receive device data from a mobile device. A record of the device data is stored in a database. A token generator creates a registration token that identifies the mobile device. The registration logic is facilitates communication between the mobile device and a vendor service when the registration token is received from the mobile device.

Abstract: Systems and methods are described herein that provide a system associated with a CRA application framework with offline capability. In one example embodiment a trip report skeleton allows trip report data about clinical research to be stored on a mobile device. The mobile device sends a trip report skeleton creation request to a server side logic using the CRA application framework. The activities related to the trip report are performed asynchronously. Therefore, when a fetch request for the trip report skeleton is issued, it is determined if the trip report skeleton is ready. When the trip report skeleton is ready, a trip report skeleton in a Self Describing Object (SDO) format is received.